Skip to main content
ArticleOPEN ACCESS

Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations

Blood
DOI: 10.1182/blood.2024025409
12Citations
Citations of this article
56Readers
Mendeley users who have this article in their library.

Your institution provides access to this article.

Abstract

The European LeukemiaNet (ELN) genetic risk classifications were developed based on data from younger adults receiving intensive chemotherapy. Emerging analyses from patients receiving less-intensive therapies prompted a proposal for an ELN genetic risk classification specifically for this patient population.

Cite

CITATION STYLE

APA

Döhner, H., DiNardo, C. D., Appelbaum, F. R., Craddock, C., Dombret, H., Ebert, B. L., … Löwenberg, B. (2024, November 21). Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations. Blood. Elsevier B.V. https://doi.org/10.1182/blood.2024025409

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free